Medicus Pharma eyes registrational study for SkinJect after positive Phase 2 data

Medicus Pharma (NASDAQ:MDCX) said on Wednesday its Phase 2 study of SkinJect (SKNJCT-003), a doxorubicin-containing microneedle array for nodular basal cell carcinoma (BCC), showed clinically meaningful activity, supporting plans to advance the therapy toward registrational development. “We believe the positive topline results from 200 ug cohort at day 57, support the therapeutic value of SkinJect and establishes the best path forward towards registrational study,” said Dr. Raza Bokhari, executive chairman and CEO of Medicus.